Sterile Fill Finish

Sterile Fill Finish
Product Description

Aseptic and Terminal sterilisationsmall moleculelarge molecule/biologicsADCsATMPSCell & Gene TherapyPeptidesOligonucleotidesRadiopharmaViral Vectors

Eramol

  • Country/Region:
    United Kingdom
  • On CPHI since:
    2026
  • Certificates:
    4
  • Employees:
    25 - 49
Company types
CMO/CDMO
Primary activities
Contract Manufacturer
Specifications
  • Details
    Aseptic and Terminal sterilisation

    small molecule
    large molecule/biologics
    ADCs
    ATMPS
    Cell & Gene Therapy
    Peptides
    Oligonucleotides
    Radiopharma
    Viral Vectors
  • Selling Points
    End to End

    Manufacture, packaging, labelling, QC testing, QP Release, storage & global distribution capabilities 

Eramol

  • Country/Region:
    United Kingdom
  • On CPHI since:
    2026
  • Certificates:
    4
  • Employees:
    25 - 49
Company types
CMO/CDMO
Primary activities
Contract Manufacturer

More Products from Eramol (4)

Eramol resources (1)

  • News New Sterile Manufacturing Facility (End to End CMO service)

    Eramol’s new sterile manufacturing facility at its Sevenoaks campus is a purpose-built, EU GMP Annex 1 aligned site designed to support early-phase sterile injectable programmes. The facility features isolator-based aseptic fill-finish and terminal sterilisation, with phase-appropriate batch sizes and a strong focus on sterility assurance and product protection, achieving <1% line losses. Fully integrated with Eramol’s wider services, the facility provides an end-to-end sterile solution including packaging and labelling, QC testing, UK/EU QP release, regulatory support, GMP/GDP storage and global distribution, with planned expansion to support later-stage and commercial manufacturing.